Post by Gubra

A meaningful milestone for Gubra! Our partner Boehringer Ingelheim today announced plans to move BI 3034701 into Phase 2 clinical development in mid-2026. The investigational peptide is a potential first-in-class triple GLP-1, GIP and NPY2 receptor agonist for obesity and related metabolic diseases. It is the first asset from a Gubra research collaboration to reach Phase 2 and a strong reflection of our ambition to help bring forward differentiated peptide therapies grounded in the biology of obesity. We are proud to see the program continue to progress with Boehringer Ingelheim. This is what long-term science and strong partnerships can make possible. Read more in our press release here: https://lnkd.in/e2w9GhPA   #Gubra #BoehringerIngelheim #ScientificPartnership #ObesityResearch #MetabolicDisease #PeptideTherapeutics #DrugDevelopment #ClinicalDevelopment #Phase2